SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.11-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Casaubon who wrote (14615)12/9/2004 9:44:03 PM
From: Biomaven  Read Replies (1) of 52153
 
there is no known clinical value associated with actually raising HDL.

Well low HDL is more strongly correlated with mortality from heart disease than is high LDL. And niacin is proven to both increase HDL and significantly reduce 6-year mortality in people with high LDL who have already had one heart attack. (See the famous CDP study re-analysis from circa 2002).

And of course to use your language, I could well say there is no known clinical value associated with actually reducing LDL
(as distinct from reducing LDL via using statins, which is a very different claim).

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News